4.7 Review

Recent advances in personalized colorectal cancer research

Journal

CANCER LETTERS
Volume 347, Issue 1, Pages 15-21

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2014.01.025

Keywords

Colorectal cancer (CRC); Biomarkers; KRAS; Monoclonal antibodies (mAbs); Oncotype; Epigenetic markers

Categories

Funding

  1. Helen and Haim Lieber Chair for Cancer Research

Ask authors/readers for more resources

Colorectal cancer is one of the most prevalent cancers and a leading cause of cancer-related death. It is also curable if detected early. The prognosis for metastatic colorectal cancer remains poor and resistance to chemotherapy is still a major obstacle in effective treatment. While many patients do not clinically benefit from chemotherapy, others experience adverse reactions resulting in dose modifications or treatment withdrawal, thereby reducing treatment efficacy. Research efforts attempt to identify reliable biomarkers which will guide clinicians in decision making, while matching suitable therapeutic regimens. We here review currently known molecular biomarkers used for the personalized treatment of colorectal cancer. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available